Citius Oncology, Inc. (CTOR) — Tangible Net Worth Ratio
Citius Oncology, Inc. (CTOR) has a Tangible Net Worth Ratio of -101.6% as of March 2026. This metric is calculated by deducting intangible assets ($71.11 Million) from net assets ($35.27 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See CTOR net asset value for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Citius Oncology, Inc. Tangible Net Worth Ratio (2022–2025)
This chart shows how Citius Oncology, Inc.'s Tangible Net Worth Ratio has changed across 4 annual periods from 2022 to 2025. As of March 2026, the ratio stands at -101.6%, reflecting net assets of $35.27 Million with intangible assets of $71.11 Million USD. Also explore CTOR year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Citius Oncology, Inc. (2022–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Citius Oncology, Inc. from 2022 to 2025, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Citius Oncology, Inc. stock valuation.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -63.6% | $44.87 Million | $73.40 Million | $100.94 Million | ▼ -4.5 pp |
| 2024 | -59.1% | $46.14 Million | $73.40 Million | $84.37 Million | ▼ -2.4 pp |
| 2023 | -56.6% | $25.54 Million | $40.00 Million | $47.73 Million | ▼ -46.4 pp |
| 2022 | -10.3% | $36.27 Million | $40.00 Million | $42.69 Million | — |